Micro-Flow Imaging: Estimation of the Contribution of Key Factors to the Variability of Subvisible Particle Count Measurement by a Nested Statistical Analysis

References

1. 1.↵
   1. Ripple D. C.,
   2. Dimitrova M. N.

   Protein Particles: What We Know and What We Do Not Know. J. Pharm. Sci. 2012, 101 (10), 3568–3579.

   OpenUrlPubMed
2. 2.↵
   1. Corvari V.,
   2. Narhi L. O.,
   3. Spitznagel T. M.,
   4. Afonina N.,
   5. Cao S.,
   6. Cash P.,
   7. Cecchini I.,
   8. DeFelippis M. R.,
   9. Garidel P.,
   10. Herre A.,
   11. Koulov A. V.,
   12. Lubiniecki T.,
   13. Mahler H.-C.,
   14. Mangiagalli P.,
   15. Nesta D.,
   16. Perez-Ramirez B.,
   17. Polozova A.,
   18. Rossi M.,
   19. Schmidt R.,
   20. Simler R.,
   21. Singh S.,
   22. Weiskopf A.,
   23. Wuchner K.

   Subvisible (2–100 μm) Particle Analysis during Biotherapeutic Drug Product Development: Part 2, Experience with the Application of Subvisible Particle Analysis. Biologicals 2015, 43 (6), 457–473.

   OpenUrl
3. 3.↵
   1. Mathonet S.,
   2. Mahler H.-C.,
   3. Esswein S. T.,
   4. Mazaheri M.,
   5. Cash P. W.,
   6. Wuchner K.,
   7. Kallmeyer G.,
   8. Das T. K.,
   9. Finkler C.,
   10. Lennard A.

   A Biopharmaceutical Industry Perspective on the Control of Visible Particles in Biotechnology-Derived Injectable Drug Products. PDA J. Pharm. Sci. Technol. 2016, 70 (4), 392–408.

   OpenUrlAbstract/FREE Full Text
4. 4.↵
   1. Langille S. E.

   Particulate Matter in Injectable Drug Products. PDA J. Pharm. Sci. Technol. 2013, 67 (3), 186–200.

   OpenUrlAbstract/FREE Full Text
5. 5.↵
   1. Filipe V.,
   2. Hawe A.,
   3. Carpenter J. F.,
   4. Jiskoot W.

   Analytical Approaches to Assess the Degradation of Therapeutic Proteins. TrAC, Trends Anal. Chem. 2013, 49, 118–125.

   OpenUrl
6. 6.↵
   1. Zölls S.,
   2. Tantipolphan R.,
   3. Wiggenhorn M.,
   4. Winter G.,
   5. Jiskoot W.,
   6. Friess W.,
   7. Hawe A.

   Particles in Therapeutic Protein Formulations, Part 1: Overview of Analytical Methods. J. Pharm. Sci. 2012, 101 (3), 914–935.

   OpenUrlCrossRefPubMed
7. 7.↵
   1. den Engelsman J.,
   2. Garidel P.,
   3. Smulders R.,
   4. Koll H.,
   5. Smith B.,
   6. Bassarab S.,
   7. Seidl A.,
   8. Hainzl O.,
   9. Jiskoot W.

   Strategies for the Assessment of Protein Aggregates in Pharmaceutical Biotech Product Development. Pharm. Res. 2011, 28 (4), 920–933.

   OpenUrlCrossRefPubMed
8. 8.↵
   1. Ratanji K. D.,
   2. Derrick J. P.,
   3. Dearman R. J.,
   4. Kimber I.

   Immunogenicity of Therapeutic Proteins: Influence of Aggregation. J. Immunotoxicol. 2014, 11 (2), 99–109.

   OpenUrlCrossRefPubMedWeb of Science
9. 9.↵
   1. Frahm G. E.,
   2. Pochopsky A. W. T.,
   3. Clarke T. M.,
   4. Johnston M. J. W.

   Evaluation of Microflow Digital Imaging Particle Analysis for Sub-Visible Particles Formulated with an Opaque Vaccine Adjuvant. PLoS One 2016, 11 (2), e0150229.

   OpenUrl
10. 10.↵
    1. Zölls S.,
    2. Weinbuch D.,
    3. Wiggenhorn M.,
    4. Winter G.,
    5. Friess W.,
    6. Jiskoot W.,
    7. Hawe A.

    Flow Imaging Microscopy for Protein Particle Analysis: A Comparative Evaluation of Four Different Analytical Instruments. AAPS J. 2013, 15 (4), 1200–1211.

    OpenUrl
11. 11.↵
    1. Sharma D. K.,
    2. King D.,
    3. Oma P.,
    4. Merchant C.

    Micro-Flow Imaging: Flow Microscopy Applied to Sub-Visible Particulate Analysis in Protein Formulations. AAPS J. 2010, 12 (3), 455–464.

    OpenUrlPubMed
12. 12.↵
    1. Sharma D. K.,
    2. Oma P.,
    3. Pollo M. J.,
    4. Sukumar M.

    Quantification and Characterization of Subvisible Proteinaceous Particles in Opalescent mAb Formulations Using Micro-Flow Imaging. J. Pharm. Sci. 2010, 99 (6), 2628–2642.

    OpenUrlPubMed
13. 13.↵
    1. Sharma D. K.,
    2. King D.,
    3. Merchant C.

    Reference Material Development for Calibration and Verification of Image-Based Particle Analyzers. Int. J. Pharm. 2011, 416 (1), 293–295.

    OpenUrlPubMed
14. 14.↵
    1. Weinbuch D.,
    2. Zölls S.,
    3. Wiggenhorn M.,
    4. Friess W.,
    5. Winter G.,
    6. Jiskoot W.,
    7. Hawe A.

    Micro-Flow Imaging and Resonant Mass Measurement (Archimedes): Complementary Methods to Quantitatively Differentiate Protein Particles and Silicone Oil Droplets. J. Pharm. Sci. 2013, 102 (7), 2152–2165.

    OpenUrl
15. 15.↵
    1. Scherer T. M.,
    2. Leung S.,
    3. Owyang L.,
    4. Shire S. J.

    Issues and Challenges of Subvisible and Submicron Particulate Analysis in Protein Solutions. AAPS J. 2012, 14 (2), 236–243.

    OpenUrlPubMed
16. 16.↵
    1. Ríos Quiroz A.,
    2. Finkler C.,
    3. Huwyler J.,
    4. Mahler H.-C.,
    5. Schmidt R.,
    6. Koulov A. V.

    Factors Governing the Accuracy of Subvisible Particle Counting Methods. J. Pharm. Sci. 2016, 105 (7), 2042–2052.

    OpenUrl
17. 17.↵
    1. Rauk A. P.,
    2. Griffiths K. L.,
    3. Gossage M. D.,
    4. Weiss W. F. IV.

    . Variability in Flow-Imaging Microscopy Measurements and Considerations for Biopharmaceutical Development. J. Pharm. Sci. 2016, 105 (11), 3296–3303.

    OpenUrl
18. 18.↵
    1. Ríos Quiroz A.,
    2. Lamerz J.,
    3. Da Cunha T.,
    4. Boillon A.,
    5. Adler M.,
    6. Finkler C.,
    7. Huwyler J.,
    8. Schmidt R.,
    9. Mahler H.-C.,
    10. Koulov A. V.

    Factors Governing the Precision of Subvisible Particle Measurement Methods: A Case Study with a Low-Concentration Therapeutic Protein Product in a Prefilled Syringe. Pharm. Res. 2016, 33 (2), 450–461.

    OpenUrl
19. 19.↵
    1. Werk T.,
    2. Volkin D. B.,
    3. Mahler H.-C.

    Effect of Solution Properties on the Counting and Sizing of Subvisible Particle Standards as Measured by Light Obscuration and Digital Imaging Methods. Eur. J. Pharm. Sci. 2014, 53, 95–108.

    OpenUrl
20. 20.↵
    1. Majumdar S.,
    2. Ford B. M.,
    3. Mar K. D.,
    4. Sullivan V. J.,
    5. Ulrich R. G.,
    6. D'Souza A. J. M.

    Evaluation of the Effect of Syringe Surfaces on Protein Formulations. J. Pharm. Sci. 2011, 100 (7), 2563–2573.

    OpenUrlPubMed
21. 21.↵
    1. Vlieland N. D.,
    2. Nejadnik M. R.,
    3. Gardarsdottir H.,
    4. Romeijn S.,
    5. Sediq A. S.,
    6. Bouvy M. L.,
    7. Egberts A. C. G.,
    8. van den Bemt B. J. F.,
    9. Jiskoot W.

    The Impact of Inadequate Temperature Storage Conditions on Aggregate and Particle Formation in Drugs Containing Tumor Necrosis Factor-Alpha Inhibitors. Pharm. Res. 2018, 35 (2), 42.

    OpenUrl
22. 22.↵
    1. Pedersen J. S.,
    2. Persson M.

    Unmasking Translucent Protein Particles by Improved Micro-Flow Imaging™ Algorithms. J. Pharm. Sci. 2014, 103 (1), 107–114.

    OpenUrl
23. 23.↵
    1. Saller V.,
    2. Hediger C.,
    3. Matilainen J.,
    4. Grauschopf U.,
    5. Bechtold-Peters K.,
    6. Mahler H.-C.,
    7. Friess W.

    Influence of Particle Shedding from Silicone Tubing on Antibody Stability. J. Pharm. Pharmacol. 2018, 70 (5), 675–685.

    OpenUrl
24. 24.↵
    1. Weiss W. F. IV.,
    2. Young T. M.,
    3. Roberts C. J.

    Principles, Approaches, and Challenges for Predicting Protein Aggregation Rates and Shelf Life. J. Pharm. Sci. 2009, 98 (4), 1246–1277.

    OpenUrlCrossRefPubMedWeb of Science
25. 25.↵
    1. Wuchner K.,
    2. Büchler J.,
    3. Spycher R.,
    4. Dalmonte P.,
    5. Volkin D. B.

    Development of a Microflow Digital Imaging Assay to Characterize Protein Particulates during Storage of a High Concentration IgG1 Monoclonal Antibody Formulation. J. Pharm. Sci. 2010, 99 (8), 3343–3361.

    OpenUrlPubMed